Jeffrey Alan Sosman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey Alan Sosman has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
- David F. McDermott
Harvard Medical School, Boston, Massachusetts
80 shared publications - Hans Hammers
Department of Hematology Oncology, The University of Texas Southwestern Medical Center, Dallas, USA
80 shared publications - Catherine J. Wu
Dana-Farber Cancer Institute
79 shared publications - David A. Braun
Yale School of Medicine, New Haven, CT, USA
79 shared publications - Destiny J. West
Brigham and Women’s Hospital 1 Department of Pathology Boston, Massachusetts
79 shared publications - Mark N. Stein
Columbia University Medical Center, New York, NY
79 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S2 shows the genomic variants detected by WES and statistical analaysis of WES data.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S2 shows the genomic variants detected by WES and statistical analaysis of WES data.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S3 shows the annotation of cells evaluated by NanoString.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S3 shows the annotation of cells evaluated by NanoString.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S1 shows the processing and review of sample processing for WES, RNAseq, and MIBI.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S1 shows the processing and review of sample processing for WES, RNAseq, and MIBI.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S4 show the comparison of cell types by MIBI across sample/response groups.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S4 show the comparison of cell types by MIBI across sample/response groups.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S5 shows the expression of protein markers by cell type subsets in MIBI data.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S5 shows the expression of protein markers by cell type subsets in MIBI data.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S6 shows the TCR/BCR repertoire metrics in RNAseq data from biopsies from patients nonresponsive to combination therapy.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S6 shows the TCR/BCR repertoire metrics in RNAseq data from biopsies from patients nonresponsive to combination therapy.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S7 shows the evaluation of TLS signatures in RNAseq and MIBI samples.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S7 shows the evaluation of TLS signatures in RNAseq and MIBI samples.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Methods contains additional methods details with a data dictionary for the supplementary tables.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Methods contains additional methods details with a data dictionary for the supplementary tables.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S9 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Tables containing sample and patient metadata, statistical results, annotation of cell types detected by MIBI, and manually reviewed variants in genes of interest.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S9 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Tables containing sample and patient metadata, statistical results, annotation of cell types detected by MIBI, and manually reviewed variants in genes of interest.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 2. List of the antibodies and dyes used for the Multiplex IF assay (panel 2).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
Supplementary Table 2. List of the antibodies and dyes used for the Multiplex IF assay (panel 2).